The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy

Abstract

Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA(+)-M2BP) was developed recently as a predictive marker of progression to liver fibrosis and hepatocellular carcinoma (HCC) in patients seropositive for hepatitis C virus (HCV). We retrospectively analyzed 16 HCV-seropositive patients who received systemic chemotherapy for hematologic malignancies to evaluate the usefulness of WFA(+)-M2BP for predicting HCV-related complications. These were defined as the onset of significant liver damage (LD) with increased HCV RNA levels, leading to interrupted or discontinued chemotherapy or the occurrence of HCC after chemotherapy. Baseline WFA(+)-M2BP levels were determined using preserved serum samples. The median level of WFA(+)-M2BP was 1.59 [cutoff index (C.O.I.) value range 0.38-6.66]. With a median follow-up of 623 days (range 120-2404), LD and HCC were observed in three and two patients, respectively. Detectable HCV RNA and WFA(+)-M2BP ≥2.0 C.O.I. at baseline were identified as risk factors for these HCV-related complications (P = 0.034 and P = 0.005, respectively). The sensitivity, specificity, and positive and negative predictive values of the WFA(+)-M2BP level (cutoff point: 2.0 C.O.I.) for the occurrence of HCV-related complications were 100.0, 81.8, 71.4, and 100.0 %, respectively. WFA(+)-M2BP may be a useful marker for the prediction of HCV-related complications in HCV-seropositive patients following systemic chemotherapy.

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

“…16 86]. M2BPGi is reportedly useful as a predictive marker for liver failure and complications after hepatectomy or transcatheter arterial chemoembolization [82,[87][88][89][90][91]. Thus, M2BPGi level reflects not only liver fibrosis but also liver function.…”

“…M2BPGi levels increase as the disease progresses. M2BPGi can be used to assess disease status, such as that of liver fibrosis [31-38, 52-58, 71-75], HCC risk [31, 32, 36, 48-51, 53, 58, 62-69, 79, 104], HCC recurrence risk [92][93][94], liver function [82,[87][88][89][90][91], and prognosis of chronic liver diseases [82][83][84][85][86], with progression of the disease. In one relevant metaanalysis, the sensitivities and specificities for predicting significant fibrosis ( ≥ F2), advanced fibrosis ( ≥ F3), and cirrhosis were 0.690, 0.764, and 0.818 and 0.778, 0.758, and 0.839, respectively [21].…”

Wisteria floribunda agglutinin‐positive human Mac‐2‐binding protein as a predictive marker of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients

“…Several unique studies have provided the means for a non‐invasive screening of liver fibrosis in HIV/HCV coinfection, using the macrophage activation marker soluble CD163 or surface‐enhanced laser desorption ionization time‐of‐flight mass spectrometry . In the present study we focused on WFA + ‐M2BP, which has multibranching and sialylated N‐glycans, and is well known as a marker of liver fibrosis for use in various types of liver disease, including hepatitis B, hepatitis C, and non‐alcoholic fatty liver disease . In liver surgery, Ishii et al .…”